Telix to Showcase Extensive Urologic Pipeline at AUA Annual Meeting including Phase III ProstACT GLOBAL Study of TLX591

Melbourne - Telix today announces five oral abstract presentations featuring the Company's late-stage theranostic programs in urology at the American Urological Association (AUA) Annual Meeting being held in San Antonio from May 3 - 6, 2024.

Presentations cover: ProstACT GLOBAL Phase III study of TLX591 (177Lu rosopatamab tetraxetan), Telix's first-in-class investigational prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy for prostate cancer and Illuccix (68Ga-PSMA-11), Telix's approved positron emission tomography (PET) imaging agent for prostate cancer.

In addition, the Company will be presenting two thought leadership sessions at the AUA Product Theater (booth #1159), featuring key opinion leaders in urologic oncology and theranostics - one on the future of kidney cancer detection and management (including the potential role of TLX250-CDx Zircaix1 PET in clear cell renal cell carcinoma), and one on Illuccix and PSMA imaging for the initial staging of prostate cancer.

Come and meet with us in person at booth #631 to discuss Telix's theranostic programs targeting PSMA, our carbonic anhydrase IX (CAIX) targeting programs in kidney, bladder and other CAIX-expressing cancers, our associated medical devices and artificial intelligence (AI), and opportunities for collaboration.

AUA oral presentation details are as follows (all times CDT)

Title: Analyzing the percentage of positive 68Ga-PSMA-PET/CT scans based on PSA ranges across distinct indications for the scan

Presenter: Maya Nicole Ataya, MD, Research Fellow at Indiana University

Date and Time: Friday, May 3 | 7:30 am - 7:40 am

Session: PD01: Prostate Cancer: Advanced (including Drug Therapy) I

Location: 301A

Title: Predicting positive 68Ga-PSMA PET/CT scans in biochemical recurrence following prostatectomy

Presenter: Maya Nicole Ataya, MD, Research Fellow at Indiana University

Date and Time: Friday, May 3 | 5:00 pm - 5:10 pm

Session: PD17: Prostate Cancer: Staging I

Location: 225D

Title: Characterizing prostate cancer risk with 68Ga-PSMA-11 PET imaging and artificial intelligence (AI)

Presenter: Simon Wail, Director of AI Research, Telix Pharmaceuticals

Date and Time: Sunday, May 5 | 7:50 am - 8:00 am

Session: PD36: Surgical Technology & Simulation: Artificial Intelligence III

Location: 301A

Title: ProstACT GLOBAL: A Phase III study of 177-lutetium rosopatamab tetraxetan plus standard of care vs. standard of care alone for adult patients with PSMA positive metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibition

Presenter: Scott Tagawa, Professor of Medicine & Urology Weill Cornell Medicine

Date and Time: Sunday, May 5 | 2:20 pm - 2:28 pm

Session: Clinical Trials in Progress, Cancer

Location: Learning Lab

Title: Identifying sites of prostate cancer recurrence in 68Ga-PSMA PET/CT based on scan indication

Presenter: Maya Nicole Ataya, MD, Research Fellow at Indiana University

Date and Time: Sunday, May 5 | 2:20 pm - 2: 30 pm

Session: PD45: Prostate Cancer: Staging II

Location: 301A

Telix AUA Product Theater listings (booth #1159):

Title: The future of kidney cancer detection and management

Presenters: Neil Shore, MD (moderator), Medical Director, Carolina Urology Research Center

Brian Shuch, MD, Director, Kidney Cancer Program UCLA

Jeremie Calais, MD, Director, Clinical Research Program, Translational Theranostics Division UCLA

Learning Objectives

Address RCC landscape changes and the necessity for early, precise detection

Showcase imaging advancements for characterizing renal masses, and

Demonstrate next-gen molecular targeted PET imaging utility through patient cases and potential clinical integration.

Date and Time: Saturday, May 4 | 2:30 pm - 3:15 pm

Location: Science and Technology Hall, Booth #1159

Title: Illuccix and PSMA imaging for the initial staging of prostate cancer

Presenters

Umesh Oza, MD, Baylor University Medical Center

Naveen Kella, MD, The Urology Place, Adjunct Assistant Professor UT Learning Objectives: Demonstrate the utilization of Illuccix for prostate cancer staging

Differentiate the advantages of gallium over conventional imaging for staging patients with suspected metastatic disease, and

Analyze patient case studies to evaluate the effectiveness of Illuccix in staging patients.

Date and Time: Sunday, May 5 | 2:30 pm - 3:15 pm

Location: Science and Technology Hall, Booth #1159

Space for both theater sessions is limited so early registration is recommended.

Illuccix has been approved by the U.S. Food and Drug Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. No other Telix product has received a marketing authorisation in any jurisdiction

Contact:

Email: info@telixpharma.com